Ebert EBF, et al. - Given clearing circulating tumour DNA (ctDNA) during first line tyrosine kinase inhibitors (TKI) treatment for epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) has been reported to be predictive of the outcomes for first and second generation TKI treatments, so, researchers undertook this prospective, multicentre analysis with 225 patients, to determine the impacts on outcome measures of ctDNA clearing in subsequent treatment lines to treatment with the third generation TKI osimertinib. They found that progression-free survival, objective response rates and disease control rates were significantly predicted by clearing all EGFR mutations from the blood following osimertinib treatment. Based on the findings, the usefulness of clearing of EGFR mutations in ctDNA following osimertinib treatment start was concluded as a positive predictor of clinical outcome in patients suffering from advanced NSCLC.